These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31743292)

  • 1. Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
    Cattaneo D; Baldelli S; Cozzi V; Fusi M; Atzori C; Micheli V; Filice C; Gervasoni C
    Ther Drug Monit; 2020 Apr; 42(2):330-334. PubMed ID: 31743292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Carbamazepine on Darunavir Trough Concentrations: When the Dose Can Make the Difference-A Case Study.
    Cattaneo D; Caloni B; Caronni S; Calvagna N; Bonini I; Giacomelli A; Gervasoni C
    Ther Drug Monit; 2024 Jun; 46(3):277-280. PubMed ID: 38723113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
    Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
    AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy.
    Israel S; Elinav H; Elazary R; Porat D; Gibori R; Dahan A; Azran C; Horwitz E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis.
    Cazzaniga A; Scrimieri R; Galli M; Maier J; Rusconi S
    AIDS; 2021 Feb; 35(2):213-218. PubMed ID: 33394669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations.
    Cattaneo D; Pagano S; Colombo ML; Giacomelli A; Gori A; Gervasoni C
    AIDS; 2024 May; 38(6):847-851. PubMed ID: 38227571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
    Denault JS; Cabot JF; Langlois H; Marcotte S; Sheehan NL
    Antivir Ther; 2019; 24(1):73-76. PubMed ID: 30353885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
    Cattaneo D; Minisci D; Cozzi V; Riva A; Meraviglia P; Clementi E; Galli M; Gervasoni C
    Antivir Ther; 2017; 22(4):353-356. PubMed ID: 28008867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
    Stader F; Decosterd L; Stoeckle M; Cavassini M; Battegay M; Saldanha SA; Marzolini C; Courlet P;
    AIDS; 2020 May; 34(6):949-952. PubMed ID: 32028327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of the Drug-Drug Interactions Between Valproic Acid and Dolutegravir-A Case Study.
    Cattaneo D; Giacomelli A; Calvagna N; Bonini I; Ridolfo AL; Gervasoni C
    Ther Drug Monit; 2024 Aug; 46(4):419-421. PubMed ID: 38758630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
    Stader F; Courlet P; Decosterd LA; Battegay M; Marzolini C
    Clin Pharmacol Ther; 2021 Apr; 109(4):1025-1029. PubMed ID: 33521960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
    Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.
    Cattaneo D; Baldelli S; Castoldi S; Charbe N; Cozzi V; Fucile S; Clementi E
    AIDS; 2014 Oct; 28(16):2477-80. PubMed ID: 25392858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxcarbazepine, an antiepileptic agent.
    Kalis MM; Huff NA
    Clin Ther; 2001 May; 23(5):680-700; discussion 645. PubMed ID: 11394728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body Fat Distribution and Metabolic Changes in a Cohort of Adolescents Living With HIV Switched to an Antiretroviral Regimen Containing Dolutegravir.
    Giacomet V; Lazzarin S; Manzo A; Paradiso L; Maruca K; Barera G; Zuccotti GV; Mora S
    Pediatr Infect Dis J; 2021 May; 40(5):457-459. PubMed ID: 33847293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings.
    Cattaneo D; Sollima S; Meraviglia P; Milazzo L; Minisci D; Fusi M; Filice C; Gervasoni C
    Drugs R D; 2020 Jun; 20(2):155-160. PubMed ID: 32189238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
    Maartens G; Boffito M; Flexner CW
    Curr Opin HIV AIDS; 2017 Jul; 12(4):355-358. PubMed ID: 28403028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice.
    Rocamora R; Peltola J; Assenza G; McMurray R; Villanueva V
    Seizure; 2020 Feb; 75():121-128. PubMed ID: 31981862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.